Alumis

Alumis, in trading debut, falls 22% from IPO price (NASDAQ:ALMS)

ismagilov Clinical-stage biopharmaceutical company Alumis (NASDAQ:ALMS) is having a rough day on its first day of trading with shares trading well below its IPO price of $16/share. As of 130p ET, shares were trading at $12.50, an almost 22% decline from its IPO price. Although the IPO was priced atContinue Reading

Alumis prices IPO at $16 per share (Pending:ALMS)

In: Finance

Olemedia/E+ via Getty Images Clinical-stage biopharmaceutical company developing oral therapies — Alumis (ALMS) priced its initial offering of 13.125M shares at $16.00 per share. Underwriters have a 30-day over-allotment option to purchase up to an additional 1,968,750 shares. Alumis (ALMS)also announced today that it has agreed to sell an additionalContinue Reading

Alumis, in trading debut, falls 22% from IPO price (NASDAQ:ALMS)

Build a generative AI assistant to enhance employee experience using Amazon Q Business | Amazon Web Services

Introducing document-level sync reports: Enhanced data sync visibility in Amazon Kendra | Amazon Web Services